earnings
confidence high
sentiment neutral
materiality 0.60
Adial Pharma Q1 net loss $2.2M; warrants raise $2.75M; AD04 Phase 2 meeting set for July
ADIAL PHARMACEUTICALS, INC.
2025-Q1 EPS reported
-$0.34
- Cash $2.4M at March 31; with $2.75M warrant proceeds, runway into Q4 2025.
- Net loss $2.2M vs $6.5M YoY; reduction due to $4.5M 2024 inducement expense not recurring.
- Entered warrant inducement: exercised 3.7M shares at $0.74, gross proceeds ~$2.75M.
- Received six-figure milestone from Adovate for asthma candidate Phase 1; eligible for up to $83M in milestones plus royalties.
- FDA supports 505(b)(2) bridging strategy; End of Phase 2 meeting planned for July 2025.